Abionyx Pharma
Manufacturing · France · 51-200 Employees
View Company Info for Free
Overview
Headquarters
33 43 Av. Georges Pompidou Bât D2, Balma...Phone Number
+33 562249706Website
www.abionyx.comRevenue
$5 MillionStock Symbol
ABNXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Abionyx Pharma
ABIONYX Pharma is a new generation biotech company that aims to contribute to health through innovative therapies in indications where there is no effective or existing treatment, even the rarest ones. Thanks to its partners in research, medicine, biopharmaceuticals and shareholding, the company innovates on a daily basis to propose drugs for the treatment of renal and ophthalmological diseases, or new HDL vectors used for targeted drug delivery.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Abionyx Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Abionyx Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Abionyx Pharma launches new products
Funding: Get notified immidiatlly once Abionyx Pharma has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check out if Abionyx Pharma is spiking on competitors!
Earning: See what the market has to say on Abionyx Pharma recently announced quarterly report
Check if Abionyx Pharma has recently received funding, and reach out quickly before it becomes old news!
Click to see if Abionyx Pharma had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Abionyx Pharma
Recommended Actions
Reach out to Masked Content who joined Abionyx Pharma as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Abionyx Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Abionyx Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Abionyx Pharma.
Abionyx Pharma financials insights
Gather financial insights about Abionyx Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Share Placement
$2.2M
2021
Share Placement
$4.6M
Abionyx Pharma Tech Stack
A closer look at the technologies used by Abionyx Pharma
Most Recent Scoops
New Hire
Executive Move
Earnings
Sales
Earnings
Sales
Funding
Funding
Funding
Abionyx Pharma News & Media
World Rare Disease Day: ABIONYX renews its commitment to treat LCAT Deficiency (Norum's disease) and provides an update on its advances
TOULOUSE, France & LAKELAND, Mich.--(BUSINESS WIRE)--ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a next generation biopharma company dedicated to the development of innovative biomedicines based on a recombinant apolipoprotein apoA-1 for the treatment of the most severe inflammatory diseases, today provides an update on its progress and confirms its commitment to the rare disease known as LCAT Deficiency or ‘Norum's disease’. About ABIONYX Pharma ABIONYX Pharma is a next-generABIONYX Pharma, winner of the France 2030 Plan’s “i-Démo” call for projects, awarded €8.7 million from the French government to fight against Sepsis, the 3rd leading cause of death worldwide
TOULOUSE, France & WESTLAKE, Calif.--(BUSINESS WIRE)--ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces today that its clinical development in sepsis has been selected as part of the “i-Démo” call for projects under the France 2030 plan, operated by Bpifrance on behalf of the French government. After 6 months of examining ABIOABIONYX Pharma announces the approval of all resolutions put to the vote at its Combined ...
Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and developmentABIONYX Pharma has completed a successful pre-IND meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis
TOULOUSE, France & LAKELAND, Mich.--(BUSINESS WIRE)--ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, today announced that the company has completed a pre-IND (Investigational New Drug Application, IND) meeting with the US Food and Drug Administration and has received feedback to support an IND filing for its candidate drug. This
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Abionyx Pharma
Sign Up For FreeTo access detailed company insights
ABIONYX Pharma is a new generation biotech company that aims to contribute to health through innovative therapies in indications where there is no effective or existing treatment, even the rarest ones. Thanks to its partners in research, medicine, biopharmaceuticals and shareholding, the company innovates on a daily basis to propose drugs for the t... Read More
